Literature DB >> 7509316

Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis.

C M Mink1, C H O'Brien, S Wassilak, A Deforest, B D Meade.   

Abstract

Elevated agglutinin titers have been shown to correlate with protection from disease following whole-cell pertussis vaccination, but the isotype and antigen specificity of human agglutinating antibodies is unknown. In 13 immunoassays, immunoglobulin G antifimbria antibodies had the strongest correlation with agglutinin titers following culture-proven infection with Bordetella pertussis (R' = 0.79; P < 0.0001) and following whole-cell pertussis vaccination (R' = 0.87, P < 0.0001).

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7509316      PMCID： PMC186231          DOI： 10.1128/iai.62.3.1118-1120.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  10 in total

1.  Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.

Authors:  D A Blumberg; C M Mink; J D Cherry; K S Reisinger; M M Blatter; B L Congeni; C L Dekker; M G Stout; J R Mezzatesta; J V Scott
Journal:  J Pediatr       Date:  1990-07       Impact factor: 4.406

2.  Development of a pertussis component vaccine in Japan.

Authors:  Y Sato; M Kimura; H Fukumi
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

3.  Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies.

Authors:  Z M Li; M J Brennan; J L David; P H Carter; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

4.  Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis.

Authors:  M J Brennan; Z M Li; J L Cowell; M E Bisher; A C Steven; P Novotny; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

5.  A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled.

Authors:  R W Steketee; D G Burstyn; S G Wassilak; W N Adkins; M B Polyak; J P Davis; C R Manclark
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

6.  Agglutinating monoclonal antibodies that specifically recognize lipooligosaccharide A of Bordetella pertussis.

Authors:  Z M Li; J L Cowell; M J Brennan; D L Burns; C R Manclark
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

7.  Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.

Authors:  C M Morgan; D A Blumberg; J D Cherry; K S Reisinger; M M Blatter; J L Blumer; C L Dekker; M G Stout; P D Christenson
Journal:  Am J Dis Child       Date:  1990-01

8.  Serum IgA antibody to Bordetella pertussis as an indicator of infection.

Authors:  J Nagel; E J Poot-Scholtens
Journal:  J Med Microbiol       Date:  1983-11       Impact factor: 2.472

9.  DTP and DTP-inactivated polio vaccines: comparison of adverse reactions and IGG, IGM and IGA antibody responses to DTP.

Authors:  O Ruuskanen; M K Viljanen; T T Salmi; O P Lehtonen; K Kouvalainen; T Peltonen
Journal:  Acta Paediatr Scand       Date:  1980-03

10.  Evaluation of a new highly purified pertussis vaccine in infants and children.

Authors:  K M Edwards; R B Bradley; M D Decker; P S Palmer; J Van Savage; J C Taylor; W D Dupont; C C Hager; P F Wright
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226
  10 in total
  7 in total

Review 1.  Laboratory diagnosis of pertussis: state of the art in 1997.

Authors:  F M Müller; J E Hoppe; C H Wirsing von König
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

Review 2.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 3.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

4.  Comparison of Western immunobloting to an enzyme-linked immunosorbent assay for the determination of anti-Bordetella pertussis antibodies.

Authors:  Stephen D Merrigan; Ryan J Welch; Christine M Litwin
Journal:  Clin Vaccine Immunol       Date:  2011-02-09

5.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  Characterization of human bactericidal antibodies to Bordetella pertussis.

Authors:  A A Weiss; P S Mobberley; R C Fernandez; C M Mink
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

7.  Serologic evidence of pertussis infection in vaccinated Iranian children.

Authors:  Anahita Sanaei Dashti; Abdollah Karimi; Reza Arjmand; Mohsen Moghadami; Taherh Kheirkhah; Farideh Shiva; Zari Gholinejad; Hassan Joulaei
Journal:  Iran J Med Sci       Date:  2012-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.